Phaseline

Targets › NMDA

NMDA: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Other; next expected readout Jul 2027.

Open in Phaseline: the race on NMDA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Hospital Universitario La FeOpioid-Free Anesthesia (OFA)
Multimodal non-opioid protocol: alpha-2 agonist (Dexmedetomidine), sodium channel blocker
ADRA2A, Ion channels, NMDAPhase 1Pain ManagementJul 2027

Conditions

Pain Management (1)

Modalities

small molecule (1)

Companies

Hospital Universitario La Fe (1)

Related targets

ADRA2A (1) Ion channels (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.